Clinical Trial

Synergistic Minimally Invasive Surgery and Deferoxamine in ICH

Study acronym: SMAD
Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This is a multicenter, randomized, open-label trial designed to evaluate the safety, feasibility, and efficacy of combining minimally invasive surgery (MIS) with intravenous deferoxamine (DFX) for the treatment of spontaneous intracerebral hemorrhage (ICH), compared to standard medical care. This trial represents the first investigation of a dual-modality approach in ICH, integrating mechanical clot evacuation with biochemical neuroprotection, with the goal of improving neurological outcomes.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-09-04; most recent amendment 2025-10-06.
Trial Details
NCT Number NCT07162363
Lead Sponsor University of Illinois at Chicago
Conditions Intracerebral Hemorrhage, ICH - Intracerebral Hemorrhage
Enrollment 240 participants
Start Date 2026-03-01
Primary Completion 2028-12-30 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-10-10